The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.

The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $32.00 expecting VRNA to rise to within 12 months (a possible 110.94% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by HC Wainwright & Co., and Verona Pharma reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a reiterated with a price target of $0.00 to $32.00. The current price Verona Pharma (VRNA) is trading at is $15.17, which is within the analyst’s predicted range.